Helicobacter pylori (H. pylori) infection plays a crucial role in the pathogenesis of gastritis, peptic ulcer, and gastric cancer. The current treatment for the eradication of H. pylori is unwieldy as relapses may occur. As H. pylori continues to resist the present antibiotic treatments, we are challenged in attempting to find alternative treatment methods; one treatment method may be the utilization of extracted oils from plants such as Pistascia lentiscus (P. lentiscus) leaves which are widely used in Mediterranean folk medicine to treat various infectious diseases, including stomach-associated diseases. Thus, this study aimed to evaluate the anti-H. pylori activity of Pistacia lentiscus essential oil (PLEO) obtained from leaves by hydro-distillation and analyzed by gas chromatography coupled to a mass spectrometry (GC-MS). H. pylori strains were isolated from Algerians symptomatic patients’ gastric biopsies and characterized for their susceptibility to PLEO using both disc diffusion and agar dilution methods. Results revealed 65 components of PLEO dominated by monoterpenes, principally were α-pinene (15.47%), limonene (14.7%) and β-myrcene (9.93%). Twenty two H. pylori strains were isolated and their antibiotic characterization revealed that 18.18% of the tested isolates were resistant to at least two of the three antibiotics belonging to the main groups of antibiotics used in therapy to eradicate H. pylori. In contrast, PLEO showed anti-H. pylori activity against all the tested strains (100%). The inhibition diameters (32 mm, 26.66 mm, 19.67 and 12.33 for the pure and diluted oil to 1/2, 1/4 and 1/8) and minimum inhibitory concentration (1/5000, v/v) affirm the strong antimicrobial activity of PLEO against H. pylori.
Salvia officinalis is an aromatic plant of Mediterranean origin traditionally used to treat inflammatory, cardiovascular, endocrine, and digestive diseases. In this work, the ability of the Salvia officinalis extract in the treatment of gastric ulcers was evaluated, and an innovative administration system was proposed to increase the therapeutic effect of this plant. Salvia officinalis ethanolic extract was prepared and analyzed by HPLC/UV-DAD and encapsulated in a matrix based on gelatin and pectin using an emulsion–coacervation process. The prepared microcapsules were analyzed by laser particle size, optical microscopy, in vitro dissolution kinetics, and ex vivo bioadhesion. In order to determine the action mechanism of Salvia officinalis extract, in the treatment of gastric ulcer, the in vivo anti-ulcerogenic activity in rats, using the ulcer model induced by ethanol; the in vivo anti-Helicobacter pylori activity; and in vitro inhibitory activity of H+/K+-ATPase were carried out. These three biological activities were evaluated for ethanolic extract and microcapsules to determine the effect of formulation on biological activities. Ethanolic extract of Salvia officinalis was mainly composed of polyphenols (chlorogenic acid 7.43%, rutin 21.74%, rosmarinic acid 5.88%, and quercitrin 14.39%). Microencapsulation of this extract allowed us to obtain microcapsules of 104.2 ± 7.5 µm in diameter, an encapsulation rate of 96.57 ± 3.05%, and adequate bioadhesion. The kinetics of in vitro dissolution of the extract increase significantly after its microencapsulation. Percentages of ulcer inhibition for 100 mg/kg of extract increase from 71.71 ± 2.43% to 89.67 ± 2.54% after microencapsulation. In vitro H+/K+-ATPase-inhibiting activity resulted in an IC50 of 86.08 ± 8.69 µM/h/mg protein for free extract and 57.43 ± 5.78 µM/h/mg protein for encapsulated extract. Anti-Helicobacter pylori activity showed a similar Minimum Inhibitory Concentration (MIC) of 50 µg/mL for the extract and microcapsules. Salvia officinalis ethanolic extract has a significant efficacy for the treatment of gastric ulcer; its mechanism of action is based on its gastroprotective effect, anti-Helicobacter pylori, and H+/K+-ATPase inhibitor. Moreover, the microencapsulation of this extract increases its gastroprotective and H+/K+-ATPase-inhibiting activities significantly.
The aim of this study was to prepare nanogels based on gelatin and xanthan-aldehyde for the enhancement of ibuprofen transdermal delivery. Firstly, the process of formulating nanogels using the reaction of Schiff’s base was optimized using experimental designs. Secondly, the structural characterization of nanogels was performed using laser particle size, zetometry, FTIR (Fourier Transform Infrared Spectroscopy), XRD (X-Ray Diffraction), SEM (scanning electron microscopy), and thermogravimetric analysis. Finally, the evaluation of pharmacological characteristics and formulation therapeutic efficacy were achieved using in vitro dissolution kinetics, ex vivo transdermal diffusion studies, and an evaluation of in vivo anti-inflammatory activity. The results of the experimental plan show that the formulations containing a ratio of 15:10 ibuprofen/polymer and a ratio of 1:2 gelatin/xanthan-aldehyde with a gelling time of 2 h exhibited the best results; the formulations showed a mean diameter of 179.9 ± 6.2 nm, a polydispersity index of 0.193, which confirms monodispersed particles, a zeta potential of 24.7 mV, denoting a high degree of particle stability, and an encapsulation rate of 93.78%. The FTIR spectroscopy analysis showed the formation of imine function in the nanogel, and scanning electron microscopy showed the globular and porous form of the formulation. The incorporation of ibuprofen into nanogels improved their in vitro dissolution kinetics and ex vivo transdermal diffusion. The incorporation of nanogels into a patch system for its in vivo anti-inflammatory activity has shown excellent efficiency with a percentage of edema inhibition at a dose of 25 mg and 50 mg of 38.77 ± 1.6% and 82.03 ± 9.03%, respectively, while the commercial reference gel presented inhibition values at a dose of 25 mg and 50 mg of 10.61 ± 1.71% and 37.03 ± 11.43%, respectively. Thus, the innovative pharmaceutical form of ibuprofen offers a promising model for enhancing drug bioavailability and therapeutic effects while reducing adverse effects.